Kalbe Genexine Biologics

KGbio is a clinical-stage biotechnology company focused on bringing biological medical innovation to markets outside the US/Canada, Western Europe and China.

KGBio's ambition is to play a leading role in increasing the availability of biologic and biosimilar medicines in the Southeast Asian region. Founded as a joint venture between Kalbe Farma, a leading healthcare and pharmaceutical company in Indonesia and Southeast Asia, and Genexine, a leading clinical-stage biotechnology company in South Korea, KGBio is positioned for strategic growth.

A combination of factors, including pricing constraints and a lack of local manufacturing capacity, have slowed the penetration of biologics in the region. Biologics have become an important category of drug development over the past 20 years, with breakthroughs in disease management, particularly in areas such as immuno-oncology, a key area for the Kalbe Group and KGBio.

KGBio has established strong clinical development and manufacturing capabilities, and plans to leverage Kalbe Farma's strength in distribution and global networks to create a broad portfolio of biologics for the Southeast Asian region.

The company has licensed two late-stage biologics and a new early-stage biologic.